An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01985126 |
Recruitment Status :
Completed
First Posted : November 15, 2013
Results First Posted : February 2, 2017
Last Update Posted : June 25, 2018
|
Sponsor:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Janssen Research & Development, LLC
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Multiple Myeloma |
Interventions |
Drug: Daratumumab 16 mg/kg (Part 1) Drug: Daratumumab 8 mg/kg (Part 1) Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine Drug: Daratumumab (Part 2) |
Enrollment | 124 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
---|---|---|
Arm/Group Description | Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity. | Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity. |
Period Title: Overall Study | ||
Started | 18 | 106 |
Completed | 0 | 0 |
Not Completed | 18 | 106 |
Reason Not Completed | ||
Death | 15 | 69 |
Lost to Follow-up | 0 | 8 |
Study Terminated By Sponsor | 1 | 22 |
Withdrawal by Subject | 2 | 7 |
Baseline Characteristics
Arm/Group Title | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Total | |
---|---|---|---|---|
Arm/Group Description | Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity. | Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity. | Total of all reporting groups | |
Overall Number of Baseline Participants | 18 | 106 | 124 | |
Baseline Analysis Population Description |
All treated Analysis Set included all participants who received at least 1 dose of daratumumab.
|
|||
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 18 participants | 106 participants | 124 participants | |
<=18 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Between 18 and 65 years |
8 44.4%
|
58 54.7%
|
66 53.2%
|
|
>=65 years |
10 55.6%
|
48 45.3%
|
58 46.8%
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 18 participants | 106 participants | 124 participants | |
64.2 (7.72) | 62.9 (10) | 63.1 (9.68) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 18 participants | 106 participants | 124 participants | |
Female |
6 33.3%
|
54 50.9%
|
60 48.4%
|
|
Male |
12 66.7%
|
52 49.1%
|
64 51.6%
|
|
Region of Enrollment
Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 18 participants | 106 participants | 124 participants |
Canada |
0 0.0%
|
22 20.8%
|
22 17.7%
|
|
Spain |
3 16.7%
|
9 8.5%
|
12 9.7%
|
|
United States |
15 83.3%
|
75 70.8%
|
90 72.6%
|
|
Stage of Disease (ISS)
[1] Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 18 participants | 106 participants | 124 participants | |
I |
2 11.1%
|
26 24.5%
|
28 22.6%
|
|
II |
8 44.4%
|
40 37.7%
|
48 38.7%
|
|
III |
8 44.4%
|
40 37.7%
|
48 38.7%
|
|
[1]
Measure Description: The International Staging System (ISS) system consists of stage I: beta2-microglobulin less than (<)3.5 milligram per liter (mg/l) and albumin greater than or equal to (>=) 3.5 gram (g)/100 ml; stage II: neither stage I nor stage III and stage III: beta2-microglobulin >= 5.5 mg/l.
|
||||
Number of Prior Lines of Therapy
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 18 participants | 106 participants | 124 participants | |
<= 3 Lines |
6 33.3%
|
19 17.9%
|
25 20.2%
|
|
> 3 Lines |
12 66.7%
|
87 82.1%
|
99 79.8%
|
|
Refractory to Proteasome Inhibitor (PI)/ Immunomodulatory Drug (IMiD)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 18 participants | 106 participants | 124 participants | |
Both a PI and IMiD |
15 83.3%
|
101 95.3%
|
116 93.5%
|
|
PI only |
1 5.6%
|
3 2.8%
|
4 3.2%
|
|
IMiD only |
0 0.0%
|
1 0.9%
|
1 0.8%
|
|
None |
2 11.1%
|
1 0.9%
|
3 2.4%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.
Results Point of Contact
Name/Title: | Senior Director Clinical Leader |
Organization: | Janssen Research & Development, LLC |
EMail: | ClinicalTrialDisclosure@its.jnj.com |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT01985126 |
Other Study ID Numbers: |
CR102651 54767414MMY2002 ( Other Identifier: Janssen Research & Development, LLC ) 2013-000752-18 ( EudraCT Number ) |
First Submitted: | July 22, 2013 |
First Posted: | November 15, 2013 |
Results First Submitted: | September 30, 2016 |
Results First Posted: | February 2, 2017 |
Last Update Posted: | June 25, 2018 |